Skip to main content

Table 4 Characteristics associated with full publication: Cox proportional hazards model analysis

From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

 

HR (95% CI)

P-value

Drug type

 ICPi

ref.

 

 Other anticancer drugs

1.1 (0.8–1.7)

0.55

Study phase

 Phase 1

ref.

 

 Phase 2 or 3

1.7 (1.1–2.6)

0.02

Multi-country study

 No

ref.

 

 Yes

1 (0.4–2.2)

0.95

Sample size

 Smaller

ref.

 

 Larger

1.4 (0.8–2.2)

0.16

  1. ICPi immune checkpoint inhibitor, HR hazard ratio, CI confidence interval, ref. reference
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us